FDA adds PML death scenario to Tecfidera label

Eric Palmer

When Biogen Idec reported last month that a patient taking its hot multiple sclerosis pill had developed a rare brain infection and died, the drugmaker said it believed the safety profile of the drug remained solid. Perhaps so, but the FDA has decided the was important enough to add a description of it on Tecfidera labels.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS